WASHINGTON DC, April 2 /PRNewswire/ -- Bavarian Nordic, the Danish-based biopharmaceutical company, recently published its 2007 Annual Report. Below is an extract of the most significant matters in the report as well as events after the balance sheet date.

Bavarian Nordic's revenue for the year 2007 was DKK 332.1 million with a loss before tax of DKK 50.5 million, which was in line with the Company's latest guidance. For 2008, Bavarian Nordic expects revenue in the region of DKK 180 million, and a pre-tax loss in the region of DKK 225 million as the first deliveries of vaccines for the US government under the RFP-3 contract are not expected to take place before 2009.

2007 outline

AMSTERDAM, The Netherlands, April 2 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that AMT's Supervisory Board has decided to propose Dr. George Morstyn to be appointed to the Supervisory Board at its Annual General Meeting of shareholders on April 16, 2008. Dr. Morstyn (MB BS PhD FRACP), who retired as Senior Vice President of Development at Amgen, was a member of Amgen's executive committee and responsible for global preclinical and clinical development as well as regulatory affairs.

LONDON, April 2 /PRNewswire/ -- Responding to news today about Government plans to extend healthcare services offered to patients and the public through community pharmacies, Paul Bennett, Chairman of the English Pharmacy Board of the Royal Pharmaceutical Society of Great Britain, said:

"It is very exciting that the Government has listened to the profession's call to extend the clinical and advisory services offered to the public. Many pharmacies in England are already providing a range of services to their local communities such as the treatment of long-term conditions including asthma and diabetes and also support services for smoking cessation.

SAN JOSE, California, April 2 /PRNewswire/ --

Micrel Inc., (Nasdaq: MCRL), an industry leader in analog, high bandwidth communications and Ethernet IC solutions, today launched the MIC47100, an 1A High Speed, NMOS LDO designed to take advantage of applications that that utilize multiple supply rails to generate a low voltage, high current power supply. The device is targeted at point-of-load, PDAs, DSPs, PLDs, FPGAs and low voltage post regulation applications. It is currently available in volume quantities and are priced at US$1.57 for 1K quantities in the MLF(R) package and US$1.62 for 1K quantities in the ePad SOIC-8 package.

LONDON, April 2 /PRNewswire/ -- Intasoft today releases its long awaited new IntaChange Enterprise change management software. The software is an easy-to-use, online system with a host of new features especially designed to make the process of change management more efficient and to improve the auditing process.

IntaChange Enterprise is essential for organisations requiring compliance with Sarbanes-Oxley or those wanting to use the ITIL framework to improve workflow and efficiency. It gives both internal and third party auditors a clear view of the entire change process.

Journalists and other readers should disregard the news release "New Release of IntaChange Web Based Change Management Software", issued earlier today. The copy released by PR Newswire was incorrect and out of date.

Contact Information: Tony Collins, Tel: +44(0)1392-447780, Fax: +44(0)1392-447781, Email: info@intasoft.net

LONDON, April 2 /PRNewswire/ --

- Premiere Virtualization Event Offers Exceptional Exposure Opportunity for Virtualization Startups

Virtualization Congress (http://www.virtualizationcongress.com), the premier vendor independent virtualization event, today officially opened its Call for Startups competition. Startup companies focused on virtualization technologies which have not launched to the market yet, or are currently operating in stealth mode, can now apply and get their chance to win a free keynote slot during the main days of the event: 15th - 16th October, 2008.

LONDON, April 2 /PRNewswire/ --

- Microsoft Research Cambridge report sees human-centred design as the vital ingredient in successfully harnessing technology's huge potential by 2020.

ANTWERP, Belgium, April 2 /PRNewswire/ -- Atlas Copco has yet again proven its world leadership in air-compressor manufacturing with the introduction of the new GA range of oil-injected compressors. Every component in the new GA range has been carefully evaluated and designed to provide Atlas Copco's customers with a product offering the highest levels of reliability and energy efficiency.

CHICAGO, April 2 /PRNewswire/ --

- Leading Expert Discusses Study During Late-Breaking Presentations at ACC

Final six-month, follow-up patient data presented yesterday during the late-breaking clinical trial sessions at the American College of Cardiology, suggest MyoCell(R) myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.